Literature DB >> 5883484

Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia.

J R Rasch, W J Mogabgab.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5883484

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother (Bethesda)


× No keyword cloud information.
  8 in total

1.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

2.  Possible influence of antibiotic therapy on usefulness of metabolic inhibition test for diagnosis of Mycoplasma pneumoniae infections.

Authors:  T F Smith; E C Herrmann
Journal:  Appl Microbiol       Date:  1971-01

3.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

4.  Mycoplasma pneumoniae infections in children.

Authors:  D Stevens; P G Swift; P G Johnston; P J Kearney; B D Corner; D Burman
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

5.  Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function.

Authors:  A R Sabato; A J Martin; B P Marmion; T W Kok; D M Cooper
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 6.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Authors:  Brad Spellberg; George H Talbot; Eric P Brass; John S Bradley; Helen W Boucher; David N Gilbert
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

7.  Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.

Authors:  S Arai; Y Gohara; K Kuwano; T Kawashima
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

8.  7-Chlorolincomycin therapy of pulmonary infections due to Myoplasma pneumoniae.

Authors:  J Axelrod; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.